Publications by authors named "M I Bethel"
Achieving bone union remains a significant clinical dilemma. The use of osteoinductive agents, specifically bone morphogenetic proteins (BMPs), has gained wide attention. However, multiple side effects, including increased incidence of cancer, has renewed interest in investigating alternatives that provide safer, yet effective bone regeneration.
View Article and Find Full Text PDFPeripheral arterial disease (PAD) is one clinical manifestation of systemic atherosclerosis and is very common. Despite its prevalence, PAD remains underdiagnosed, undertreated, and understudied. The most common symptom in patients with PAD is intermittent claudication (IC), or pain in the lower extremities with walking or exertion, which is relieved after a short period of rest.
View Article and Find Full Text PDFPregnancy-associated breast cancer is challenging to treat. Treatment with chemotherapeutic agents such as anthracyclines poses a risk of cardiotoxicity, despite being considered safe after the second trimester of pregnancy. Management requires multidisciplinary comanagement with cardio-obstetrics, cardiology-oncology, maternal-fetal medicine, and oncology.
View Article and Find Full Text PDFArticle Synopsis
- Researchers analyzed cardiovascular event patterns in patients with type 2 diabetes using data from the TECOS trial, focusing on a composite of major adverse cardiovascular events (MACE-4).
- They found that event rates for both fatal and nonfatal outcomes remained relatively constant over the trial period, suggesting traditional prediction models can be reliably used for estimating event accrual.
- The study highlighted the importance of monitoring the adjudication gap, which is the time between when events occur and when they are officially recognized, as it improves over the course of the trial.
Objective: The glucagon-like peptide-1 receptor agonist dulaglutide reduced MACE in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. This article expores the relationship of selected biomarkers to both dulaglutide and major adverse cardiovascular events (MACE).
Research Design And Methods: In this post hoc analysis, stored fasting baseline and 2-year plasma samples from 824 REWIND participants with MACE during follow-up and 845 matched non-MACE participants were analyzed for 2-year changes in 19 protein biomarkers.